{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:49:38Z","timestamp":1792007378864,"version":"4.4.0"},"reference-count":80,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020638","name":"Allergan Aesthetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>OnabotulinumtoxinA has been licensed for the treatment of upper facial lines for over 20\u2009years. Patient benefits extend well beyond correction of the lines themselves\u2014including positive effects on confidence, self\u2010esteem, feelings of attractiveness, and age appearance. Regulatory bodies recommend that patient\u2010reported outcomes (PROs) are routinely included in registrational studies to ensure the patient perspective is considered. Essential guidance is available from regulators and other expert groups to aid the development, validation, and use of appropriate PROs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To reflect on the evolution of patient experience data collection in onabotulinumtoxinA aesthetic medicine development programs within the context of PRO usage across approved botulinum toxins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literature searches were performed to identify relevant publications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Several PRO instruments have been rigorously developed and validated following regulatory guidance and implemented in onabotulinumtoxinA clinical programs. These include the Facial Line Outcomes Questionnaire (FLO\u201011) and Facial Line Satisfaction Questionnaire (FLSQ). The data generated have supported the licensing process and enabled a deeper understanding of patient perspectives. Although these instruments were developed for clinical studies, the concepts obtained directly from patient interviews align with patient goals in clinical practice. Similarly, PROs such as FACE\u2010Q are now employed more widely across approved botulinum toxins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A patient\u2010centric approach, in lockstep with regulatory requirements, has been central to onabotulinumtoxinA development. Awareness of the comprehensive benefits of aesthetic treatments should continue to improve based on increasingly robust PROs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.70311","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T05:55:09Z","timestamp":1750658109000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Revealing the Patient Perspective: Evolution of Patient\u2010Reported Outcome Measures in Botulinum Toxin Studies in Aesthetic Medicine"],"prefix":"10.1111","volume":"24","author":[{"given":"Steven","family":"Dayan","sequence":"first","affiliation":[{"name":"Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology University of Illinois at Chicago  Chicago Illinois USA"},{"name":"DeNova Research  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Z.","family":"Rivkin","sequence":"additional","affiliation":[{"name":"David Geffen\/UCLA School of Medicine University of California at Los Angeles  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Private Practice, Skin Concept  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean D. A.","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Development Head for Toxins, Allergan Aesthetics, an AbbVie Company  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Patel","sequence":"additional","affiliation":[{"name":"Patient Centered Outcomes Research, Allergan Aesthetics, an AbbVie Company  Irvine California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Global Lead Neurotoxin, Global Aesthetics Medical Affairs, Allergan Aesthetics, an AbbVie Company  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"e_1_2_16_2_1","unstructured":"American Society of Plastic Surgeons \u201cASPS Procedural Statistics Release \u201d(2023) (accessed May 2025) www.plasticsurgery.org\/documents\/news\/statistics\/2023\/plastic\u2010surgery\u2010statistics\u2010report\u20102023.pdf."},{"key":"e_1_2_16_3_1","unstructured":"International Society of Aesthetic Plastic Surgery \u201cISAPS International Survey on Aesthetic\/Cosmetic Procedures Performed in 2023 \u201d(accessed May 2025) www.isaps.org\/media\/rxnfqibn\/isaps\u2010global\u2010survey_2023.pdf."},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.121356"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.PRS.0000076504.79727.62"},{"key":"e_1_2_16_6_1","first-page":"1","article-title":"One\u2010Year, Randomised, Multicenter, Two\u2010Period Study of the Safety and Efficacy of Repeated Treatments With Botulinum Toxin Type A in Patients With Glabellar Lines","volume":"7","author":"Carruthers A.","year":"2004","journal-title":"Journal of Clinical Research"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000128"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000220"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000357"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001414"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001612"},{"key":"e_1_2_16_12_1","unstructured":"Food and Drug Administration \u201cGuidance for Industry. Patient\u2010Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims \u201d(accessed May 2025) www.fda.gov\/media\/77832\/download."},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12117"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12166"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojz015"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001878"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2022.08.063"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000000146"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001779"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002153"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001883"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000002079"},{"key":"e_1_2_16_23_1","first-page":"27","article-title":"Patient\u2010Reported Outcomes in Chinese Subjects Treated With onabotulinumtoxinA for Crow's Feet Lines","volume":"14","author":"Wu Y.","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-017-0844-9"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002143"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002047"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002216"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15947"},{"key":"e_1_2_16_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-008-9199-6"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04071.x"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003585"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001920"},{"key":"e_1_2_16_33_1","first-page":"413","article-title":"A Multicenter, Randomized, Double\u2010Blind, Placebo\u2010Controlled, Single\u2010Dose, Phase III, Non\u2010Inferiority Study Comparing prabotulinumtoxinA and onabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients","volume":"40","author":"Rzany B. J.","year":"2020","journal-title":"Aesthetic Surgery Journal"},{"key":"e_1_2_16_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjac210"},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001903"},{"key":"e_1_2_16_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000002864"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000003456"},{"key":"e_1_2_16_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.15783"},{"key":"e_1_2_16_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz003"},{"key":"e_1_2_16_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz248"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjab329"},{"key":"e_1_2_16_42_1","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/DSS.0000000000003594","article-title":"Liquid AbobotulinumtoxinA: Pooled Data From Two Double\u2010Blind, Randomized, Placebo\u2010Controlled Phase III Studies of Glabellar Line Treatment","volume":"48","author":"Hilton S.","year":"2022","journal-title":"Dermatologic Surgery"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6130"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-022-03164-3"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12408"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17217"},{"key":"e_1_2_16_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000004152"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1313"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000006327"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5013"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2006.32325.x"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"e_1_2_16_53_1","unstructured":"European Medicines Agency \u201cReflection Paper on the Regulatory Guidance for the Use of Health\u2010Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products \u201d(2005) (accessed May 2025) www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010regulatory\u2010guidance\u2010use\u2010health\u2010related\u2010quality\u2010life\u2010hrql\u2010measures\u2010evaluation_en.pdf."},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.04054.x"},{"key":"e_1_2_16_55_1","unstructured":"Food and Drug Administration \u201cGuidance for Industry. Upper Facial Lines: Developing Botulinum Toxin Drug Products \u201d(2014) (accessed May 2025) www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/upper\u2010facial\u2010lines\u2010developing\u2010botulinum\u2010toxin\u2010drug\u2010products."},{"key":"e_1_2_16_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.014"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.06.013"},{"key":"e_1_2_16_58_1","unstructured":"\u201cBOTOX Cosmetic. Highlights of Prescribing Information \u201d(accessed May 2025) www.rxabbvie.com\/pdf\/botox\u2010cosmetic_pi.pdf."},{"key":"e_1_2_16_59_1","unstructured":"\u201cVistabel. Summary of Product Characteristics \u201d(accessed May 2025) www.medicines.ie\/medicines\/vistabel\u201034207\/spc#tabs."},{"key":"e_1_2_16_60_1","unstructured":"Center for Drug Evaluation \u201cDrug Information. Botox \u201d(2021) (accessed May 2025) www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=9e9301b08a23302d1e18e4e535a721b7."},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjae220"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.027"},{"key":"e_1_2_16_63_1","unstructured":"\u201cFACE\u2010Q Aesthetics \u201d(accessed May 2025) https:\/\/qportfolio.org\/face\u2010q\/aesthetics."},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262313"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cps.2012.12.001"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/1090820X13510170"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000000895"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-022-02974-9"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.11.003"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.0018"},{"key":"e_1_2_16_71_1","unstructured":"Food and Drug Administration \u201cPatient\u2010Focused Drug Development: Collecting Comprehensive and Representative Input. Guidance for Industry Food and Drug Administration Staff and Other Stakeholders \u201d(2020) (accessed May 2025) www.fda.gov\/media\/139088\/download."},{"key":"e_1_2_16_72_1","unstructured":"U.S. Government \u201c21st Century Cures Act \u201d(2016) (accessed May 2025) www.congress.gov\/114\/plaws\/publ255\/PLAW\u2010114publ255.pdf."},{"key":"e_1_2_16_73_1","unstructured":"Food and Drug Administration \u201cPDUFA VI: Fiscal Years 2018\u20132022 \u201d(accessed May 2025) www.fda.gov\/industry\/prescription\u2010drug\u2010user\u2010fee\u2010amendments\/pdufa\u2010vi\u2010fiscal\u2010years\u20102018\u20102022."},{"key":"e_1_2_16_74_1","unstructured":"Food and Drug Administration \u201cPatient\u2010Focused Drug Development: Methods to Identify What Is Important to Patients. Guidance for Industry Food and Drug Administration Staff and Other Stakeholders \u201d(2022) (accessed May 2025) www.fda.gov\/media\/131230\/download."},{"key":"e_1_2_16_75_1","unstructured":"Food and Drug Administration \u201cPatient\u2010Focused Drug Development: Selecting Developing or Modifying Fit\u2010for\u2010Purpose Clinical Outcome Assessments. Guidance for Industry Food and Drug Administration Staff and Other Stakeholders \u201d(2022) (accessed May 2025) www.fda.gov\/media\/159500\/download."},{"key":"e_1_2_16_76_1","unstructured":"Food and Drug Administration \u201cPatient\u2010Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision\u2010Making. Guidance for Industry Food and Drug Administration Staff and Other Stakeholders \u201d(2023) (accessed May 2025) www.fda.gov\/media\/166830\/download."},{"key":"e_1_2_16_77_1","unstructured":"Center for Drug Evaluation \u201cGuidelines for the Use of Patient\u2010Reported Outcomes in Clinical Development of Drugs (Draft for Comments) \u201d(2021) (accessed May 2025) www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=8a900c1173e7aaf72ea3724796cebbeb."},{"key":"e_1_2_16_78_1","unstructured":"Center for Drug Evaluation \u201cNotice on the Public Solicitation of Comments on the Technical Guidelines for Patient\u2010Centered Clinical Trial Design (Draft for Comments) \u201d(2022) (accessed May 2025) www.cde.org.cn\/main\/news\/viewInfoCommon\/0cccaa1f5aeb73dcebf7d4d3e3e88b1c."},{"key":"e_1_2_16_79_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cPMDA's Patient Participation Activities \u201d(2021) (accessed May 2025) www.pmda.go.jp\/files\/000243873.pdf."},{"key":"e_1_2_16_80_1","unstructured":"Pharmaceuticals and Medical Devices Agency \u201cGuidance on Patient Participation \u201d(2021) (accessed May 2025) www.pmda.go.jp\/files\/000243407.pdf."},{"key":"e_1_2_16_81_1","unstructured":"European Medicines Agency \u201cEMA Regulatory Science to 2025: Strategic Reflection \u201d(accessed May 2025) www.ema.europa.eu\/en\/documents\/regulatory\u2010procedural\u2010guideline\/ema\u2010regulatory\u2010science\u20102025\u2010strategic\u2010reflection_en.pdf."}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T05:31:11Z","timestamp":1755581471000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1111\/jocd.70311"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70311","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"2025-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70311"}}